Results 291 to 300 of about 38,769 (305)
Some of the next articles are maybe not open access.
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Diabetologia, 2018Subodh Verma +2 more
exaly
SGLT2 inhibitors in clinical practice
The Lancet Diabetes & EndocrinologyLars, Rydén, Anna, Norhammar
openaire +2 more sources
Dapagliflozin, an SGLT2 inhibitor, for diabetes
The Lancet, 2010Markolf, Hanefeld, Thomas, Forst
openaire +2 more sources
SGLT2 inhibitors and cardiovascular outcomes
Drug and Therapeutics Bulletin, 2017openaire +2 more sources
Kidney stones and SGLT2 inhibitors
Clinical and Experimental NephrologySatoru Kuriyama, Kimiyoshi Ichida
openaire +2 more sources
The expanding résumé of SGLT2 inhibitors
The Lancet Diabetes & Endocrinology, 2019openaire +2 more sources
SGLT2 inhibitors: are they safe?
Postgraduate Medicine, 2018Theodosios D Filippatos, Moses Elisaf
exaly
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
JACC: CardioOncologyMohamed S Dabour +2 more
exaly